Crohn'
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Moderate to severe (CDAI 220-400) patients. Patients who are introduced anti-TNFa antibody as induction therapy. Patients approving the study consent.
Exclusion criteria
Exclusion criteria: Patients in 16 weeks after last biologics dosing or after bowel resection. Patients with stoma. Parenteral nutrition dependent patients with short bowel syndrome or others. Biologics intolerance. Patients judged as inadequate at the discretion of physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The occurrence of relapse (Relapse was defined by: (1) increase in CDAI of at least 70 points from the baseline score with a total score of at least 220, (2) shortening of biologics dosing interval (3) introduction of a new treatment for active Crohn's disease) | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate, safety assesment Others | — |
Countries
Japan
Contacts
Fukuoka University Chikushi Hospital Depertment of Gastroenterology